
- /
- Supported exchanges
- / US
- / PRME.NASDAQ
Prime Medicine, Inc. Common Stock (PRME NASDAQ) stock market data APIs
Prime Medicine, Inc. Common Stock Financial Data Overview
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Prime Medicine, Inc. Common Stock data using free add-ons & libraries
Get Prime Medicine, Inc. Common Stock Fundamental Data
Prime Medicine, Inc. Common Stock Fundamental data includes:
- Net Revenue: 3 846 K
- EBITDA: -200 004 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.44
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prime Medicine, Inc. Common Stock News

Cystic Fibrosis Foundation expands funding for Prime Medicine
CAMBRIDGE, Mass. - Prime Medicine, Inc. (NASDAQ:PRME), a $562 million market cap biotechnology company whose stock has surged nearly 47% year-to-date, announced Wednesday that the Cystic Fibrosis Foun...


Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from th...

Prime Medicine chief scientific officer to depart, will serve as consultant
Prime Medicine , Inc. (NASDAQ:PRME), a biotechnology company with a market capitalization of $630 million, announced Monday that Jeremy Duffield, M.D., Ph.D., FRCP will step down from his position as ...

Prime Medicine stock soars amid gene editing sector momentum
Investing.com -- Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month. The gene ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.